Palatin Seeks NYSE Relisting, $15M Offering After Delisting, Reverse Split

TL;DR

**PTN is a high-risk bet on a biotech trying to relist on NYSE American and fund its pipeline after a reverse split and delisting, making this offering a make-or-break moment.**

AI Summary

Palatin Technologies, Inc. (PTN) is filing an S-1/A to register a public offering of up to 2,307,692 shares of common stock, along with Series J and Series K common warrants, and pre-funded warrants. The offering aims to raise capital, with an assumed combined public offering price of $6.50 per share and accompanying warrants. The company recently underwent a one-for-fifty reverse stock split effective August 12, 2025, and its common stock was delisted from the NYSE American on May 7, 2025, now trading on the OTCQB under 'PTNT' at $7.10 as of October 16, 2025. A key closing condition for this offering is the re-listing of PTN's common stock on the NYSE American. Palatin reported positive Phase 2 topline results in March 2025 for co-administration of bremelanotide with tirzepatide for obesity, showing increased weight loss, and positive Phase 2 results in March 2025 for PL8177 for ulcerative colitis, with one-third of patients achieving clinical remission. The company projects IND filings for a novel once-weekly MC4R peptide agonist and PL7737 for obesity in Q1 2026. Significant operating losses since inception raise substantial doubt about its ability to continue as a going concern, necessitating this financing. Proceeds will be available for immediate use, despite uncertainties regarding business plan implementation.

Why It Matters

This S-1/A filing is critical for Palatin Technologies as it seeks to raise up to $15 million through a public offering, a lifeline given its significant operating losses and 'going concern' doubts. The re-listing on NYSE American is a non-negotiable closing condition, directly impacting investor confidence and liquidity, especially after its May 7, 2025 delisting. For investors, the offering's structure with common stock and multiple warrant series introduces complexity and potential dilution, while the assumed $6.50 offering price is below the OTCQB's $7.10, suggesting a discount to attract capital. The company's competitive position in obesity and inflammatory diseases hinges on successful clinical trials and securing this financing to advance its pipeline against larger pharmaceutical players.

Risk Assessment

Risk Level: high — The filing explicitly states 'significant operating losses since our inception and our need to obtain additional financing has caused management to determine there is substantial doubt regarding our ability to continue as a going concern.' Furthermore, the company's common stock was delisted from the NYSE American on May 7, 2025, due to low selling price, and re-listing is a closing condition for this offering, indicating significant financial and operational instability.

Analyst Insight

Investors should approach PTN with extreme caution, recognizing the high risk associated with its 'going concern' status and recent delisting. Consider the potential for significant dilution from the offering and the uncertainty of NYSE American re-listing. Only investors with a high-risk tolerance and a strong belief in the company's pipeline, particularly the obesity and ulcerative colitis programs, should consider a position, and even then, only after thorough due diligence on the offering terms and the company's ability to meet the re-listing condition.

Financial Highlights

debt To Equity

0.0

revenue

$0

operating Margin

N/A

total Assets

$12.7M

total Debt

$0

net Income

$-10.7M

eps

$-0.11

gross Margin

N/A

cash Position

$1.9M

revenue Growth

N/A

Key Numbers

• 2,307,692 — Shares of Common Stock offered (Maximum number of shares in the public offering)
• $6.50 — Assumed combined public offering price (Midpoint price per share of Common Stock and accompanying Common Warrants)
• $0.0001 — Exercise price of Pre-Funded Warrants (Nominal exercise price for Pre-Funded Warrants)
• 7.0% — Underwriting discounts and commissions (Cash fee percentage of aggregate purchase price)
• 2% — Underwriter Warrants percentage (Percentage of shares sold in offering granted as warrants to underwriters)
• 346,153 — Over-allotment option shares (Additional shares A.G.P. can purchase (15% of offering))
• $7.10 — Last reported sale price on OTCQB (Price per share on October 16, 2025, prior to the offering)
• 1-for-50 — Reverse Stock Split ratio (Ratio of reverse stock split effective August 12, 2025)
• 18 months — Series J Common Warrant expiration (Expiration period for Series J Warrants, or 31 days post-FDA IND acceptance for obesity compound)
• 5 years — Series K Common Warrant expiration (Expiration period for Series K Warrants, subject to earlier termination conditions)

Key Players & Entities

• PALATIN TECHNOLOGIES INC (company) — Registrant in S-1/A filing
• Stephen T. Wills (person) — Executive Vice President, Chief Financial Officer and Chief Operating Officer
• A.G.P./Alliance Global Partners (company) — Sole book-running manager for the offering
• Laidlaw & Company (UK) Ltd. (company) — Lead manager for the offering
• NYSE American LLC (regulator) — Former and target listing exchange for PTN common stock
• U.S. Food and Drug Administration (regulator) — Regulatory body for drug approvals
• Cosette Pharmaceuticals, Inc. (company) — Acquired PTN's product Vyleesi in December 2023
• Thompson Hine LLP (company) — Legal counsel for the registrant
• Sullivan & Worcester LLP (company) — Legal counsel for the registrant
• Securities and Exchange Commission (regulator) — Filing authority for S-1/A

FAQ

Risk Factors

• Substantial doubt about going concern [high — financial]: The company has incurred significant operating losses since its inception and has a history of losses. This raises substantial doubt about its ability to continue as a going concern. The company's ability to continue operations is dependent on its ability to raise capital through this offering and future financing activities.
• Dependence on regulatory approvals [high — regulatory]: Palatin's success is heavily reliant on the successful development and regulatory approval of its drug candidates, particularly bremelanotide and PL8177. Delays or failures in clinical trials or regulatory submissions could significantly impact the company's future prospects and ability to generate revenue.
• Competition in obesity and inflammatory disease markets [medium — market]: The markets for obesity treatments and inflammatory diseases are highly competitive, with numerous established pharmaceutical companies and emerging biotechs developing novel therapies. Palatin faces competition from existing treatments and pipeline candidates from competitors, which could limit market penetration and pricing power.
• Reliance on key personnel and third-party manufacturers [medium — operational]: The company's operations depend on the expertise of its key scientific and management personnel. Furthermore, Palatin relies on third-party contract manufacturing organizations (CMOs) for the production of its drug candidates, introducing risks related to supply chain disruptions, quality control, and manufacturing capacity.
• Dilution from future financings [medium — financial]: The company has a history of seeking external financing to fund its operations. Future equity financings, including this offering, may result in significant dilution to existing shareholders, impacting the value of their holdings.
• Re-listing requirement for NYSE American [high — regulatory]: A critical closing condition for this offering is the re-listing of Palatin's common stock on the NYSE American. Failure to meet the re-listing requirements could jeopardize the offering, impacting the company's ability to raise necessary capital.
• Volatility of OTCQB trading [low — market]: The company's common stock is currently trading on the OTCQB, which generally has lower trading volumes and higher price volatility compared to major exchanges like the NYSE American. This can impact liquidity and price discovery for investors.

Industry Context

Palatin operates in the highly competitive biopharmaceutical sector, focusing on peptide therapeutics for metabolic and inflammatory diseases. The obesity market is experiencing significant innovation with the rise of GLP-1 agonists, creating both opportunities and intense competition. The inflammatory disease space, particularly for conditions like ulcerative colitis, also sees ongoing research and development from numerous players.

Regulatory Implications

Palatin's drug development pipeline is subject to stringent FDA regulations, requiring successful completion of clinical trials and rigorous review processes for market approval. The company's ability to secure re-listing on the NYSE American is also a critical regulatory hurdle for this offering.

What Investors Should Do

1. Evaluate the clinical trial data for bremelanotide and PL8177.
2. Assess the company's ability to secure future funding.
3. Monitor the NYSE American re-listing progress.
4. Consider the competitive landscape for obesity and inflammatory disease treatments.

Key Dates

• 2025-08-12: Reverse Stock Split — Effective 1-for-50 reverse stock split, aimed at increasing the per-share price and potentially meeting exchange listing requirements.
• 2025-05-07: Delisting from NYSE American — Common stock delisted from NYSE American, now trading on OTCQB, highlighting prior listing challenges and impacting liquidity.
• 2025-03-01: Positive Phase 2 Results for Bremelanotide/Tirzepatide — Topline results showed increased weight loss when co-administered for obesity, a key therapeutic area for the company.
• 2025-03-01: Positive Phase 2 Results for PL8177 — Results for ulcerative colitis showed one-third of patients achieving clinical remission, indicating potential for a significant unmet need.
• 2026-01-01: Projected IND Filings — Anticipated IND filings for a novel once-weekly MC4R peptide agonist and PL7737 for obesity, signaling progression in pipeline development.

Glossary

S-1/A

An amendment to a registration statement filed with the SEC, used when a company is offering securities to the public. (This document details Palatin's public offering and provides crucial information about its business, financials, and risks.)

Reverse Stock Split

A corporate action where a company reduces the number of its outstanding shares by consolidating them, increasing the per-share price. (Palatin recently executed a 1-for-50 reverse stock split, impacting share count and potentially aiming to meet listing requirements.)

Pre-funded Warrants

Warrants that allow an investor to purchase shares at a nominal exercise price, often used in offerings to allow immediate exercise and ownership while deferring capital gains. (Offered in this filing, they provide immediate participation for investors while potentially simplifying the capital structure.)

Going Concern

An accounting term indicating that a company is expected to remain in business for the foreseeable future. (Palatin's S-1/A explicitly states substantial doubt about its ability to continue as a going concern due to operating losses.)

IND Filing

Investigational New Drug application, submitted to the FDA to seek permission to begin clinical trials in humans. (Palatin projects IND filings for new obesity drug candidates, a critical step in drug development.)

MC4R Peptide Agonist

A type of drug that activates the melanocortin 4 receptor, which plays a role in appetite regulation and energy balance, often targeted for obesity treatment. (Palatin is developing a novel MC4R peptide agonist for obesity, indicating a focus on this metabolic pathway.)

Underwriting Discounts and Commissions

Fees paid by the issuer to the underwriters for their services in selling the securities. (This offering includes 7.0% in underwriting discounts and commissions, impacting the net proceeds received by Palatin.)

Year-Over-Year Comparison

This S-1/A filing follows a period of significant operational activity and strategic shifts for Palatin Technologies. Key differences from prior filings would likely include updated financial statements reflecting continued operating losses, the recent reverse stock split (1-for-50), delisting from the NYSE American, and the crucial positive Phase 2 clinical trial results for bremelanotide/tirzepatide and PL8177. The current filing also explicitly addresses the substantial doubt about the company's ability to continue as a going concern, a risk factor that may have been less pronounced or absent in earlier disclosures.

Key Financial Figures

• $0.01 — 2 shares of our common stock, par value $0.01 (the "Common Stock"), together with Ser
• $6.00 — panying Common Warrants will be between $6.00 and $7.00. The assumed combined public
• $7.00 — mmon Warrants will be between $6.00 and $7.00. The assumed combined public offering
• $6.50 — ock and accompanying Common Warrants is $6.50 per share of Common Stock and accompany
• $0 — d to the public in this offering, minus $0.0001, and the exercise price of each Pr
• $0.0001 — rice of each Pre-Funded Warrant will be $0.0001 per share. The Pre-Funded Warrants will
• $7.10 — ce of our Common Stock on the OTCQB was $7.10 per share. The actual public offering p
• $6.4999 — ck and accompanying Common Warrants and $6.4999 per Pre-Funded Warrant and accompanying
• $157,500 — scounts and commissions payable will be $157,500 and the total proceeds to us, before ex
• $2,092,494 — proceeds to us, before expenses will be $2,092,494 . Delivery of the securities is expect

Filing Documents

• ptn_s1a.htm (S-1/A) — 531KB
• ptn_ex47.htm (EX-4.7) — 96KB
• ptn_ex48.htm (EX-4.8) — 97KB
• ptn_ex49.htm (EX-4.9) — 94KB
• ptn_ex51.htm (EX-5.1) — 13KB
• ptn_ex232.htm (EX-23.2) — 2KB
• ptn_ex107.htm (EX-FILING FEES) — 67KB
• ptn_s1aimg3.jpg (GRAPHIC) — 8KB
• ptn_s1aimg2.jpg (GRAPHIC) — 49KB
• ptn_s1aimg1.jpg (GRAPHIC) — 8KB
• ptn_ex51img2.jpg (GRAPHIC) — 5KB
• ptn_ex51img1.jpg (GRAPHIC) — 9KB
• 0001654954-25-011938.txt ( ) — 1131KB
• ptn_ex107_htm.xml (XML) — 6KB

USE OF PROCEEDS

USE OF PROCEEDS 13

DILUTION

DILUTION 14 DIVIDEND POLICY 16

DESCRIPTION OF SECURITIES OFFERED

DESCRIPTION OF SECURITIES OFFERED 16

UNDERWRITING

UNDERWRITING 22 LEGAL MATTERS 26 EXPERTS 26 WHERE YOU CAN FIND MORE INFORMATION 27 INFORMATION WE INCORPORATE BY REFERENCE 28 i Table of Contents CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This prospectus, including the documents incorporated by reference, contains, and any prospectus supplement may contain, "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. These statements relate to future events or to our future financial performance and involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Forward-looking statements include, but are not limited to, statements about: our significant operating losses since our inception and our need to obtain additional financing has caused management to determine there is substantial doubt regarding our ability to continue as a going concern; our ability to obtain additional financing on terms acceptable to us, or at all, including unavailability of funds or delays in receiving funds as a result of economic disruptions; our expectation that we will incur losses for the foreseeable future and may never achieve or maintain profitability; our business, financial condition, and results of operations may be adversely affected by increases in costs of and delays in conducting human clinical trials and the performance of our contractors and suppliers, reduction in our productivity or the productivity of our contractors and suppliers, supply chain constraints, and labor shortages; whether Cosette Pharmaceuticals, Inc. ("Cosette"), which acquired our product Vyleesi (the trade name for bremelanotide for treatment of hyperactive sexual desire disorder in premenopausal women) in December 2023, will have sufficient sa

View Full Filing

View this S-1/A filing on SEC EDGAR